Pharmed animals go to market
Pharmaceutical firms could soon be making a fortune from cloning, writes Charles Arthur
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.What sheep and goats can produce
Product: Human Factor IX
Use: blood clotting factor
Company: PPL Therapeutics
Value: pounds 2m per sheep
Available: if clinical trials succeed, within 10 years
Product: human alpha-1-antitrypsin
Use: to treat cystic fibrosis
Company: PPL Therapeutics
Value: probably thousands per sheep
Available: in clinical trials
Product: Human fibrinogen and factor VII
Use: blood clotting factors
Company: PPL Therapeutics
Value: pounds 500,000 per sheep
Available: within 10 years
Product: Human Factor VIII
Use: the essential blood clotting element for the majority of haemophiliacs
Company: licensed to Baxter Healthcare and Bayer
Value: pounds 10m per sheep or goat
Available: unknown
Product: Human antithrombin III
Use: blood plasma protein for accident victims and organ recipients
Company: Genzyme
Value: probably many thousands per goat
Available: in human trials
IN THE new world of "pharming" - using farm animals to produce pharmaceutically useful products - there was no bluster in the announcement this week by PPL Therapeutics that 50 cloned sheep could satisfy the pounds 100m world market for the Factor IX blood clotting protein.
It is only the start of a huge industry, made possible by the twin technologies of genetic engineering and cloning.
Where once the most valuable capital item a technology company owned was a factory, in future it will be a living, breathing animal. It will naturally generate enough of some valuable protein to make it a better wage-earner than any City slicker. And it won't even demand a company car: a big enough field with nice grass will suffice.
But for the companies, defending their property - and trying to extend it - will become an ever bigger business. PPL has already been thwarted in its wish to produce transgenic animals which produce the far more valuable Factor VIII clotting protein. That is used to treat the majority of haemophiliacs (unlike Factor IX, which is used to treat those with the rarer form, haemophilia B). The world market for Factor VIII is worth half a billion pounds. But the Scripps Institute, in La Jolla, California, has the patent on the gene that encodes the production of the protein. And it has licensed its use to Baxter Healthcare and Bayer - but not PPL.
Other companies are developing pigs whose organs are coated with human proteins, so that their kidneys, lungs and hearts could be transplanted into humans, where the numbers on waiting lists typically outnumber donors by three to one.
How much could the involuntary organ donors be worth? Presently there are just 45,000 human transplants annually. But there is no official market in organs. However, a recent estimate by analysts at Salomon Brothers reckoned that if we could use pig organs, they would create a $6bn (pounds 3.75 bn) market, in which 455,000 transplants from animals would be performed. That would make each animal worth just pounds 25,000 - implying that the figures are probably underestimates.
Given the choice between dying and paying huge amounts for a pig organ, rich people would surely choose the latter.
The technology underlying the implementation of all these methods, though, is cloning. Breeding a transgenic animal with another, normal one always carried the risk that the money-making gene would be lost. By cloning from the embryo or the adult of the transgenic animal - techniques that PPL has demonstrated are feasible - the companies can rest assured that their investments will continue for generations.
What cattle can produce
Product: Human growth hormone
Use: treatment of dwarfism and AIDS-related illnesses
Company: Genzyme
Value: up to pounds 6m per cow
Available: soon in human clinical trials
Product: beta-interferon
Use: treatment of multiple sclerosis
Company: Genzyme
Value: up to pounds 1m per cow
Available: approaching human clinical trials
Product: Human serum albumin
Use: in blood transfusions
Company: Advanced Cell Technology
Value: pounds 150,000 per cow
Available: just announced
What pigs produce
Product: "humanised" hearts, kidneys, lungs
Use: transplant operations to replace failing human organs
Company: Imutran, Alexion, Novartis, Nextran
Value: if legalised, a $6bn industry by 2010
Available: depends on medical studies on associated risks
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments